Recruiting
An Investigational Immuno-therapy Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Solid Cancers That Are Advanced or Have Spread - CA020-002
Updated: 29 September, 2021 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Location(s)
Recruiting
Treatment Options
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Participant must consent for pretreatment and on treatment tumor biopsy samples - For Part 1C tumor biopsies are optional - Nonsmall cell lung cancer (NSCLC) without prior treatment in the advanced or metastatic setting (Part 2C) - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - Must have received, and progressed or been intolerant to, at least 1 standard treatment regimen in the advanced or metastatic setting (Part 1A, 1B and 1C) - Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria; radiographic tumor assessment performed within 28 days before randomization Exclusion Criteria: - Primary central nervous system (CNS) disease, or tumors with CNS metastases as the only site of disease. Controlled brain metastases will be allowed to enroll - Other active malignancy requiring concurrent intervention - Uncontrolled/significant heart disease - History of chronic hepatitis [except for hepatocellular carcinoma (HCC)] - Active, known, or suspected autoimmune disease Other protocol defined inclusion/exclusion criteria apply
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
